Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Scientists reveal earliest evidence for shifting of Earth’s crust - 22025 Yachting Editors' Choice Awards: Yachts
- 3UN torture cm'tee report flags Israel for allegedly mistreating journalists, detainees, ex-MAG
- 4Israel halts defense sales to France, citing 'hostile attitude,' sources tell 'Post'
- 5Venezuelan President Maduro arrives in New York following U.S. capture: Full coverage
- Avoid Slam: Clearing the Street for the Eventual fate of Standard Size Trucks
- Vote in favor of the wide open action that revives your brain and soul!
- The Magnificence of Do-It-Yourself Skincare: Regular Recipes and Tips
- Don't plan to cook on Thanksgiving? Here are the restaurants and fast food places that are scheduled to be open
- Figure out How to Recognize the Right Areas for 5G Pinnacles\
- Starfront Observatories: A haven for distant stargazers
- Figure out How to Modify Your Pre-assembled Home for Greatest Solace and Stylish Allure
- Dear Santa: I want Botox. Why cosmetic procedures are topping holiday wish lists.
- 3D Printers for Specialists
